FENC
Fennec Pharmaceuticals Inc.
Biotechnology
Market Cap$194M
5Y Perf.-6.4%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
FENC vs PTCT vs SRPT vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
PTCT
PTC Therapeutics, Inc.
Biotechnology
Market Cap$6.11B
5Y Perf.+45.3%
SRPT
Sarepta Therapeutics, Inc.
Biotechnology
Market Cap$2.11B
5Y Perf.-86.9%
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.57B
5Y Perf.-61.8%
FENC vs PTCT vs SRPT vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FENC | PTCT | SRPT | RARE |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $194M | $6.11B | $2.11B | $2.57B |
| Revenue (TTM) | $39M | $827M | $2.18B | $669M |
| Net Income (TTM) | $-7M | $-187M | $65M | $-609M |
| Gross Margin | 93.1% | 49.7% | 34.4% | 83.6% |
| Operating Margin | -12.0% | -8.3% | -1.9% | -83.9% |
| Forward P/E | 54.3x | 9.5x | 5.9x | — |
| Total Debt | $19M | $492M | $1.04B | $1.28B |
| Cash & Equiv. | $27M | $985M | $801M | $434M |
FENC vs PTCT vs SRPT vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FENC
PTCT
SRPT
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Fennec Pharmaceutic… (FENC) | 100 | 93.6 | -6.4% |
| PTC Therapeutics, I… (PTCT) | 100 | 145.3 | +45.3% |
| Sarepta Therapeutic… (SRPT) | 100 | 13.1 | -86.9% |
| Ultragenyx Pharmace… (RARE) | 100 | 38.2 | -61.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FENC vs PTCT vs SRPT vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SRPT leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. PTC Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. FENC also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
FENC
Fennec Pharmaceuticals Inc.
The Growth Leader
FENC is the clearest fit if your priority is growth.
- 123.7% revenue growth vs SRPT's 15.6%
Best for: growth
PTCT
PTC Therapeutics, Inc.
The Income Pick
PTCT is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- beta 1.03
- Rev growth 114.5%, EPS growth 264.5%, 3Y rev CAGR 35.3%
- 8.5% 10Y total return vs SRPT's 13.2%
- Lower volatility, beta 1.03, current ratio 2.35x
Best for: income & stability and growth exposure
SRPT
Sarepta Therapeutics, Inc.
The Value Play
SRPT carries the broadest edge in this set and is the clearest fit for value and quality.
- Better valuation composite
- 3.0% margin vs RARE's -91.0%
- 1.9% ROA vs RARE's -45.8%, ROIC -31.4% vs -89.4%
Best for: value and quality
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Angle
RARE lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FENC | 123.7% revenue growth vs SRPT's 15.6% |
| Value | SRPT | Better valuation composite |
| Quality / Margins | SRPT | 3.0% margin vs RARE's -91.0% |
| Stability / Safety | PTCT | Beta 1.03 vs SRPT's 1.95 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PTCT | +73.3% vs SRPT's -45.4% |
| Efficiency (ROA) | SRPT | 1.9% ROA vs RARE's -45.8%, ROIC -31.4% vs -89.4% |
FENC vs PTCT vs SRPT vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2020
FY 2025
Segment breakdown not available.
FY 2025
FENC vs PTCT vs SRPT vs RARE — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPTCTLAGGINGRARE
Who Leads Where
PTCT leads in 2 of 6 categories
SRPT leads 1 • FENC leads 0 • RARE leads 0 • 2 tied
Explore the data ↓RAREUltragenyx Pharmaceut…
0leads
FENCFennec Pharmaceutical…
0leads
SRPTSarepta Therapeutics,…
1leads
PTCTPTC Therapeutics, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs SRPTvs FENCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SRPT4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
PTCT5/6
Risk & VolatilityBeta, volatility, and downside exposure
PTCT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SRPT leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SRPT is the larger business by revenue, generating $2.2B annually — 56.3x FENC's $39M. SRPT is the more profitable business, keeping 3.0% of every revenue dollar as net income compared to RARE's -91.0%. On growth, FENC holds the edge at +78.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | FENCFennec Pharmaceut… | PTCTPTC Therapeutics,… | SRPTSarepta Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $39M | $827M | $2.2B | $669M |
| EBITDAEarnings before interest/tax | -$5M | -$37M | -$6M | -$536M |
| Net IncomeAfter-tax profit | -$7M | -$187M | $65M | -$609M |
| Free Cash FlowCash after capex | -$8M | -$169M | $107M | -$487M |
| Gross MarginGross profit ÷ Revenue | +93.1% | +49.7% | +34.4% | +83.6% |
| Operating MarginEBIT ÷ Revenue | -12.0% | -8.3% | -1.9% | -83.9% |
| Net MarginNet income ÷ Revenue | -17.9% | -22.6% | +3.0% | -91.0% |
| FCF MarginFCF ÷ Revenue | -20.6% | -20.4% | +4.9% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +78.7% | -76.8% | -1.9% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +89.1% | -100.3% | +162.6% | -17.2% |
SRPT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — FENC and SRPT each lead in 2 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, PTCT's 6.3x EV/EBITDA is more attractive than FENC's 55.6x.
| Metric | FENCFennec Pharmaceut… | PTCTPTC Therapeutics,… | SRPTSarepta Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Market CapShares × price | $194M | $6.1B | $2.1B | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $187M | $5.6B | $2.3B | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -433.13x | 9.47x | -2.80x | -4.48x |
| Forward P/EPrice ÷ next-FY EPS est. | 54.27x | — | 5.91x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 55.57x | 6.27x | — | — |
| Price / SalesMarket cap ÷ Revenue | 4.09x | 3.53x | 0.96x | 3.82x |
| Price / BookPrice ÷ Book value/share | — | — | 1.83x | — |
| Price / FCFMarket cap ÷ FCF | 7.21x | 8.70x | — | — |
Evenly matched — FENC and SRPT each lead in 2 of 5 comparable metrics.
Profitability & Efficiency
Evenly matched — PTCT and SRPT each lead in 3 of 8 comparable metrics.
Profitability & Efficiency
SRPT delivers a 4.9% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), PTCT scores 7/9 vs RARE's 4/9, reflecting strong financial health.
| Metric | FENCFennec Pharmaceut… | PTCTPTC Therapeutics,… | SRPTSarepta Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | — | +4.9% | -6.1% |
| ROA (TTM)Return on assets | -15.0% | -6.8% | +1.9% | -45.8% |
| ROICReturn on invested capital | — | — | -31.4% | -89.4% |
| ROCEReturn on capital employed | +9.0% | +55.9% | -24.0% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 | 4 | 4 |
| Debt / EquityFinancial leverage | — | — | 0.91x | — |
| Net DebtTotal debt minus cash | -$7M | -$492M | $238M | $842M |
| Cash & Equiv.Liquid assets | $27M | $985M | $801M | $434M |
| Total DebtShort + long-term debt | $19M | $492M | $1.0B | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | -1.57x | -1.67x | -14.00x | -14.49x |
Evenly matched — PTCT and SRPT each lead in 3 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PTCT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PTCT five years ago would be worth $18,943 today (with dividends reinvested), compared to $2,391 for RARE. Over the past 12 months, PTCT leads with a +73.3% total return vs SRPT's -45.4%. The 3-year compound annual growth rate (CAGR) favors PTCT at 9.9% vs SRPT's -46.0% — a key indicator of consistent wealth creation.
| Metric | FENCFennec Pharmaceut… | PTCTPTC Therapeutics,… | SRPTSarepta Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -9.8% | -4.0% | -6.4% | +10.7% |
| 1-Year ReturnPast 12 months | +11.6% | +73.3% | -45.4% | -27.4% |
| 3-Year ReturnCumulative with dividends | -12.8% | +32.7% | -84.3% | -44.5% |
| 5-Year ReturnCumulative with dividends | +15.9% | +89.4% | -71.5% | -76.1% |
| 10-Year ReturnCumulative with dividends | -42.3% | +852.1% | +13.2% | -59.4% |
| CAGR (3Y)Annualised 3-year return | -4.5% | +9.9% | -46.0% | -17.8% |
PTCT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
PTCT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
PTCT is the less volatile stock with a 1.03 beta — it tends to amplify market swings less than SRPT's 1.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PTCT currently trades 84.2% from its 52-week high vs SRPT's 45.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FENCFennec Pharmaceut… | PTCTPTC Therapeutics,… | SRPTSarepta Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.78x | 1.03x | 1.95x | 1.36x |
| 52-Week HighHighest price in past year | $9.92 | $87.50 | $44.14 | $42.37 |
| 52-Week LowLowest price in past year | $5.65 | $39.53 | $10.42 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +69.9% | +84.2% | +45.2% | +61.6% |
| RSI (14)Momentum oscillator 0–100 | 53.4 | 40.0 | 48.6 | 67.7 |
| Avg Volume (50D)Average daily shares traded | 177K | 1.1M | 2.9M | 1.8M |
PTCT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: FENC as "Buy", PTCT as "Buy", SRPT as "Buy", RARE as "Buy". Consensus price targets imply 159.7% upside for FENC (target: $18) vs 26.7% for SRPT (target: $25).
| Metric | FENCFennec Pharmaceut… | PTCTPTC Therapeutics,… | SRPTSarepta Therapeut… | RAREUltragenyx Pharma… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $18.00 | $98.00 | $25.29 | $48.36 |
| # AnalystsCovering analysts | 7 | 26 | 54 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.1% | 0.0% | +1.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
PTCT leads in 2 of 6 categories (Total Returns, Risk & Volatility). SRPT leads in 1 (Income & Cash Flow). 2 tied.
Best OverallPTC Therapeutics, Inc. (PTCT)Leads 2 of 6 categories
Loading custom metrics...
FENC vs PTCT vs SRPT vs RARE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FENC or PTCT or SRPT or RARE a better buy right now?
For growth investors, Fennec Pharmaceuticals Inc.
(FENC) is the stronger pick with 123. 7% revenue growth year-over-year, versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 9. 5x trailing P/E, making it the more compelling value choice. Analysts rate Fennec Pharmaceuticals Inc. (FENC) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FENC or PTCT or SRPT or RARE?
On forward P/E, Sarepta Therapeutics, Inc.
is actually cheaper at 5. 9x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — FENC or PTCT or SRPT or RARE?
Over the past 5 years, PTC Therapeutics, Inc.
(PTCT) delivered a total return of +89. 4%, compared to -76. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: PTCT returned +852. 1% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FENC or PTCT or SRPT or RARE?
By beta (market sensitivity over 5 years), PTC Therapeutics, Inc.
(PTCT) is the lower-risk stock at 1. 03β versus Sarepta Therapeutics, Inc. 's 1. 95β — meaning SRPT is approximately 90% more volatile than PTCT relative to the S&P 500.
05Which is growing faster — FENC or PTCT or SRPT or RARE?
By revenue growth (latest reported year), Fennec Pharmaceuticals Inc.
(FENC) is pulling ahead at 123. 7% versus 15. 6% for Sarepta Therapeutics, Inc. (SRPT). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, PTCT leads at 35. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FENC or PTCT or SRPT or RARE?
PTC Therapeutics, Inc.
(PTCT) is the more profitable company, earning 39. 4% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -79. 5% for RARE. At the gross margin level — before operating expenses — PTCT leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FENC or PTCT or SRPT or RARE more undervalued right now?
On forward earnings alone, Sarepta Therapeutics, Inc.
(SRPT) trades at 5. 9x forward P/E versus 54. 3x for Fennec Pharmaceuticals Inc. — 48. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FENC: 159. 7% to $18. 00.
08Which pays a better dividend — FENC or PTCT or SRPT or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is FENC or PTCT or SRPT or RARE better for a retirement portfolio?
For long-horizon retirement investors, PTC Therapeutics, Inc.
(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +852. 1% 10Y return). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTCT: +852. 1%, SRPT: +13. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FENC and PTCT and SRPT and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(FENC: 78.7% · PTCT: -76.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.